CEACAM6 and acute lymphoblastic leukemia: As determined in our large cohort of patients treated on ALL BFM 95 protocol, no prognostic significance of CD66c could be revealed in general, nor when we analyzed separate risk groups or TEL/AML1pos, BCR/ABLpos, hyperdiploid and other B-precursor ALL cases separately.